Alfasigma USA

Formed to bring the portfolio of its Italian parent directly to North American prescribers, Alfasigma USA is the dedicated US commercial subsidiary of Alfasigma S.p.A., the Bologna-headquartered pharmaceutical group created in 2016 through the merger of Alfa Wassermann and Sigma-Tau. The parent operates in more than 90 countries and employs over 3,000 people globally, with a broad product portfolio spanning gastroenterology, hepatology, metabolism and rare disease.

US Commercial and Medical Affairs Operations

Alfasigma USA manages the full commercial lifecycle for its prescription medicines in the United States, covering regulatory submissions to the FDA, medical affairs, pharmacovigilance and market access. The subsidiary works directly with physicians, gastroenterologists, specialist prescribers, pharmacists and payer organisations to support appropriate product access and patient support programmes.

The gastroenterology and hepatology franchise is a core focus of the US operation, reflecting the parent group's longstanding research heritage in digestive health and liver function. Alfasigma USA operates within the frameworks established by the FDA and applicable federal healthcare regulations, functioning as an accountable commercial and regulatory presence rather than relying on third-party licensing or distribution arrangements.

Further information is available at alfasigmausa.com.